Pharmacokinetics and Pharmacodynamics Practice Questions

Q: What is the half-life of nicotine in blood?

2 hours. ***2 hours*** - Nicotine has a **relatively short half-life** in the blood, typically around 2 hours, contributing to frequent dosing in tobacco users. - This rapid elimination means that nicotine concentrations decrease significantly within a few hours after the last dose, leading to **withdrawal symptoms** or cravings. *15 minutes* - A 15-minute half-life would imply an **extremely rapid clearance**, which is not characteristic of nicotine. - Such quick elimination would make it very difficult to maintain consistent drug levels and would lead to immediate, intense withdrawal. *5 hours* - While longer than the actual half-life, 5 hours is still within the realm of substances requiring **multiple daily doses**. - However, it would mean nicotine levels would remain elevated for a longer period than observed, potentially delaying withdrawal. *24 hours* - A 24-hour half-life would mean nicotine would accumulate significantly in the body with daily use, leading to **prolonged effects** and a much slower decline in concentrations after cessation. - This half-life is typical for drugs designed for **once-daily dosing**, which is not the case for nicotine.

Q: Which of the following statements about transdermal drug delivery systems is false?

Good option in emergency situations. ***Option D: Good option in emergency situations*** - Transdermal drug delivery systems have a **slow onset of action** due to the time required for drug absorption through the skin layers. - This characteristic makes them **unsuitable for emergency situations** where immediate therapeutic effect is critical for patient stabilization. - Emergency situations require drugs with **rapid onset** via routes like intravenous, intramuscular, or sublingual administration. *Option A: Applied to chest, abdomen and back* - This statement is TRUE. Transdermal patches are commonly applied to areas with **good blood supply** and **minimal hair**, such as the chest, abdomen, and back. - These sites provide a relatively **large surface area** for absorption and allow for discreet placement with consistent drug delivery. *Option B: Drug is delivered at a constant rate* - This statement is TRUE. A primary advantage of transdermal systems is their ability to provide **controlled and sustained release** of medication over an extended period (typically 24-72 hours). - This constant delivery helps maintain **steady-state therapeutic drug levels** and minimizes fluctuations in plasma concentration, reducing side effects. *Option C: Fentanyl is used* - This statement is TRUE. **Fentanyl** is a potent opioid commonly delivered via transdermal patches for **chronic pain management**. - Its transdermal formulation ensures **continuous analgesia** over 72 hours and bypasses first-pass metabolism, improving bioavailability and making it effective for long-term use.

Q: Among the following statins, which has the longest half-life?

Rosuvastatin. **Rosuvastatin** - **Rosuvastatin** has the longest half-life among the commonly used statins, approximately **19 hours**, allowing for consistent lipid-lowering effects. - Its prolonged presence in the body contributes to its effectiveness in reducing **LDL-C** at lower doses. *Pravastatin* - **Pravastatin** has a relatively short half-life of about **1.8 hours**, requiring daily dosing to maintain therapeutic concentrations. - Its hydrophilic nature means it is less likely to penetrate non-hepatic tissues, potentially reducing extrahepatic side effects. *Simvastatin* - **Simvastatin** has a short half-life of about **3 hours**, necessitating daily administration. - It is a **prodrug** that requires hepatic activation to its active beta-hydroxy acid form. *Lovastatin* - **Lovastatin** also has a short half-life, around **3 hours**, and is a **prodrug** like simvastatin. - It is often recommended to be taken in the evening due to the diurnal rhythm of cholesterol synthesis.

Q: Which of the following statements about oral iron preparations is correct?

Different preparations have different bioavailability. ***Different preparations have different bioavailability*** - The **bioavailability** of oral iron preparations varies depending on the specific salt used, its formulation, and the presence of absorption enhancers or inhibitors. - This difference in absorption impacts the required dose and efficacy in treating **iron deficiency anemia**. *Most commonly used preparation is ferrous gluconate* - **Ferrous sulfate** is the most commonly prescribed and cost-effective oral iron preparation due to its high iron content and good bioavailability. - While ferrous gluconate is used, its iron content is lower than ferrous sulfate, making it less frequently the primary choice. *Ferrous fumarate is most efficient* - While **ferrous fumarate** has a high elemental iron content, its efficiency doesn't necessarily surpass that of ferrous sulfate or other preparations when considering factors like bioavailability and side effect profile. - **Ferrous sulfate** is often considered efficient due to its balance of elemental iron content, bioavailability, and cost-effectiveness. *Ferric preparations are more effective* - **Ferrous (Fe2+)** iron is generally better absorbed than **ferric (Fe3+)** iron, as ferric iron needs to be reduced to its ferrous form before absorption. - Unless specifically formulated for enhanced absorption (e.g., ferric maltol), ferric preparations are typically *less* effective for initial iron repletion.

Q: Which of the following is not excreted by the kidney?

Moxifloxacin. ***Moxifloxacin*** - Moxifloxacin is primarily metabolized in the **liver** and excreted through bile and feces. - This characteristic makes it a suitable choice for patients with significant **renal impairment** as dose adjustments are generally not required. *Ciprofloxacin* - Ciprofloxacin is predominantly excreted by the **kidneys** through both glomerular filtration and tubular secretion. - Dose adjustments are crucial in patients with **renal dysfunction** to prevent accumulation and toxicity. *Ofloxacin* - Ofloxacin is largely excreted unchanged in the **urine**, making renal excretion its primary elimination pathway. - **Dose reduction** is necessary for patients with impaired renal function. *Levofloxacin* - Levofloxacin is primarily eliminated via **renal excretion**, with a significant portion appearing in the urine as unmetabolized drug. - Patients with **kidney disease** require appropriate dose adjustments.

Q: Which of the following is a characteristic of simvastatin?

Derived from fungal metabolite. ***Derived from fungal metabolite*** - **Simvastatin** and lovastatin are **naturally-derived statins** obtained from **fungal metabolites** (*Aspergillus terreus*), distinguishing them from synthetic statins like atorvastatin, rosuvastatin, and pravastatin [2]. - This is the **most distinguishing characteristic** for classification purposes, as it represents the drug's origin and places it in a specific subclass of HMG-CoA reductase inhibitors. - The discovery of fungal-derived statins led to the development of the entire statin drug class. *Prodrug requiring hepatic activation* - While **simvastatin** is a **lactone prodrug** requiring hepatic hydrolysis to its active beta-hydroxy acid form, this is a pharmacokinetic property shared with lovastatin [1]. - This is a characteristic but not the most distinguishing feature for classification. *Specific CYP3A4 substrate with high interaction potential* - **Simvastatin** is extensively metabolized by **CYP3A4**, leading to significant drug-drug interactions with CYP3A4 inhibitors (e.g., ketoconazole, erythromycin, grapefruit juice). - While clinically important, many drugs are CYP3A4 substrates, making this less distinctive as a defining characteristic. *Short half-life requiring evening dosing* - **Simvastatin** has a **short half-life** (2-3 hours) and is preferably administered in the evening because cholesterol synthesis is highest at night. - This is a dosing consideration based on pharmacokinetics rather than a fundamental distinguishing characteristic of the drug's identity.

Q: Which is the longest acting anti-cholinesterase?

Echothiophate. ***Echothiophate*** - **Echothiophate** is an **organophosphate** compound that irreversibly inhibits acetylcholinesterase, leading to a prolonged duration of action, often measured in weeks. - Due to its **long-acting** and irreversible nature, it is primarily used in ophthalmic preparations for glaucoma but is not commonly used systemically. *Pyridostigmine* - **Pyridostigmine** is a medium-acting anticholinesterase, typically lasting **3-6 hours**, and is commonly used for the chronic management of **myasthenia gravis**. - Its effects are **reversible**, binding to the enzyme for a limited period. *Ambenonium* - **Ambenonium** has a longer duration of action than pyridostigmine, typically lasting **4-8 hours**, but is still considered a reversible inhibitor. - It was historically used for **myasthenia gravis** but is now less common due to the availability of other effective treatments. *Edrophonium* - **Edrophonium** is a very short-acting anticholinesterase, with effects lasting only **5-15 minutes**, making it ideal for the **Tensilon test** to diagnose myasthenia gravis and differentiate between myasthenic and cholinergic crises. - Its rapid onset and brief duration are due to its **reversible** and transient binding to acetylcholinesterase.

Q: Volume of distribution of a drug is 500 ml and target concentration of drug in blood is 5 g/L. 20% of administered drug is reached to systemic circulation. What will be the loading dose of that drug -

12.5 gm. ***12.5 gm*** - The formula for loading dose (LD) is: LD = (Target Concentration × Volume of Distribution) / Bioavailability. - Given: Target Concentration = 5 g/L, Volume of Distribution = 500 mL = 0.5 L, Bioavailability = 20% = 0.2. - So, LD = (5 g/L × 0.5 L) / 0.2 = 2.5 g / 0.2 = **12.5 g**. *1 gm* - This value would be obtained if the target concentration was 2 g/L with 100% bioavailability, or if the calculation incorrectly handled the volume or bioavailability factor. - It does not account for the specified **bioavailability of 20%** or the given target concentration and volume of distribution. *5 gm* - This result would be obtained if the bioavailability was assumed to be 50% (LD = 2.5 g / 0.5 = 5 g), or if the volume of distribution was incorrectly used in the calculation. - This option does not correctly factor in the **20% bioavailability** of the administered drug. *25 gm* - This value would result from mistakes such as dividing by bioavailability of 10% instead of 20% (LD = 2.5 g / 0.1 = 25 g), or by multiplying bioavailability instead of dividing by it. - This answer significantly **overestimates** the required dose, which could lead to drug toxicity.

Q: Regarding the concepts of efficacy and potency of a drug, which of the following statements is FALSE?

ED50 of the drug corresponds to efficacy. ***ED50 of the drug corresponds to efficacy*** - **ED50** (median effective dose) is the dose at which 50% of individuals exhibit the specified effect; it quantifies **potency**, not efficacy. - **Efficacy** refers to the maximum effect a drug can produce, while potency refers to the amount of drug needed to produce an effect. *In a clinical setup, efficacy is more important than potency* - **Efficacy** determines the maximal therapeutic benefit a drug can achieve for a patient, making it crucial for clinical outcomes. - While **potency** influences the dose required, a highly potent drug that is not very efficacious may not be clinically useful. *Drugs that produce a similar pharmacological effect can have different levels of efficacy* - Two drugs might act on the same receptor but elicit different maximal responses, indicating varying **efficacy**. - For example, a **partial agonist** and **full agonist** interacting with the same receptor will have different efficacies. *In the log dose response curve, the height of the curve corresponds with efficacy* - The **maximal response** or plateau of the dose-response curve represents the **efficacy** of a drug. - A higher plateau on the curve indicates a drug with greater intrinsic activity achieving a larger effect.

Question 1

What is the half-life of nicotine in blood?

Accepted Answer

2 hours

Answer

15 minutes

Answer

5 hours

Answer

24 hours

Question 2

Which of the following statements about transdermal drug delivery systems is false?

Accepted Answer

Good option in emergency situations

Answer

Applied to chest, abdomen and back

Answer

Drug is delivered at a constant rate

Answer

Fentanyl is used

Question 3

Among the following statins, which has the longest half-life?

Accepted Answer

Rosuvastatin

Answer

Pravastatin

Answer

Simvastatin

Answer

Lovastatin

Question 4

Which of the following statements about oral iron preparations is correct?

Accepted Answer

Different preparations have different bioavailability

Answer

Most commonly used preparation is ferrous gluconate

Answer

Ferrous fumarate is most efficient

Answer

Ferric preparations are more effective

Question 5

Which of the following is not excreted by the kidney?

Accepted Answer

Moxifloxacin

Answer

Ciprofloxacin

Answer

Ofloxacin

Answer

Levofloxacin

Question 6

Which of the following is a characteristic of simvastatin?

Accepted Answer

Derived from fungal metabolite

Answer

Specific CYP3A4 substrate with high interaction potential

Answer

Prodrug requiring hepatic activation

Answer

Short half-life requiring evening dosing

Question 7

Which is the longest acting anti-cholinesterase?

Accepted Answer

Echothiophate

Answer

Pyridostigmine

Answer

Ambenonium

Answer

Edrophonium

Question 8

Which statement best describes first-order kinetics in pharmacokinetics?

Accepted Answer

Elimination of the drug is proportional to the serum concentration

Answer

Absorption of the drug is independent of the serum concentration

Answer

Absorption of the drug is proportional to the serum concentration

Answer

Elimination of the drug is independent of the serum concentration

Question 9

Volume of distribution of a drug is 500 ml and target concentration of drug in blood is 5 g/L. 20% of administered drug is reached to systemic circulation. What will be the loading dose of that drug -

Accepted Answer

12.5 gm

Answer

1 gm

Answer

5 gm

Answer

25 gm

Question 10

Regarding the concepts of efficacy and potency of a drug, which of the following statements is FALSE?

Accepted Answer

ED50 of the drug corresponds to efficacy

Answer

Drugs that produce a similar pharmacological effect can have different levels of efficacy

Answer

In a clinical setup, efficacy is more important than potency

Answer

In the log dose response curve, the height of the curve corresponds with efficacy

Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics — MCQs

On this page

Practice by Chapter

Want unlimited practice?